The present invention relates to preparation and biological evaluation of 3-acetoxy-17-acetamido-16-formyl-androst-517-diene (4) and 3-acetoxy2'-chloro-5-androsteno[1716-b]pyridine (5) as gastric proton pump inhibitor and their comparison to that of omeprazole a clinically employed anti-gastric ulcer drug. Compound (4) exhibited dose dependent inhibition of histamine-stimulated acid secretion in gastric parietal cell with an IC50 value comparable to cimetidine. No mortality or behavioral abnorma...

The present invention relates to preparation and biological evaluation of 3-acetoxy-17-acetamido-16-formyl-androst-517-diene (4) and 3-acetoxy2?-chloro-5-androsteno[1716-b]pyridine (5) as gastric proton pump inhibitor and their comparison to that of omeprazole a clinically employed anti-gastric ulcer drug. Compound (4) exhibited dose dependent inhibition of histamine-stimulated acid secretion in gastric parietal cell with an IC50 value comparable to cimetidine. No mortality or behavioral abnorma...

The present invention relates to a novel nitrile glycoside of Formula (I) named NIAZIRIDIN and to analogues and derivatives thereof. The present invention also relates to a process for the isolation of a novel nitrile glycoside of Formula (I) below named NIAZIRIDIN and its derivatives and analogues by bioactivity-guided fractionation from the pods of Moringa oleifera. The present invention particularly relates to the bioenhancing activity of the novel nitrile glycoside of Formula (I) below named...

The present invention relates to an improved process for conversion of cyanopyridines to nicotinamides. More particularly the present invention relates to preparation of nicotinamides and isonicotinamides which finds its usage in the preparation of anti-TB drug i.e. isoniazid and as an intermediate of vitamin B12. The present invention also relates to a process for a catalyst useful for the preparation of nicotinamide and isonicotinamide.

The present invention relates to targets for Human microRNAs in Avian Influenza Virus (H5N1) Genome and provides specific miRNA targets against H5N1 virus. Existing therapies for Avian flu are of limited use primarily due to genetic re-assortment of the viral genome generating novel proteins and thus escaping immune response. In animal models baculovirus-derived recombinant H5 vaccines were immunogenic and protective but results in humans were disappointing even when using high doses. Currently ...

The present invention relates to a novel nitrile glycoside of Formula (I) named NIAZIRIDIN and to analogues and derivatives thereof. The present invention also relates to a process for the isolation of a novel nitrile glycoside of Formula (I) below named NIAZIRIDIN and its derivatives and analogues by bioactivity-guided fractionation from the pods of Moringa oleifera. The present invention particularly relates to the bioenhancing activity of the novel nitrile glycoside of Formula (I) below named...

The present invention provides an adenine modified solid ordered mesoporous bifunctional organo-inorganic silica-based catalyst its method of preparation and also a process for the production of cyclic carbonates of the formula hereinbelowwherein R═H CH2Cl CH3 C4H9 C6H11 C6H5.

The present invention relates to an improved process for conversion of cyanopyridines to nicotinamides. More particularly the present invention relates to preparation of nicotinamides and isonicotinamides which finds its usage in the preparation of anti-TB drug i.e. isoniazid and as an intermediate of vitamin B12. The present invention also relates to a process for a catalyst useful for the preparation of nicotinamide and isonicotinamide.